We are live on ! Find out more
MAIA icon

MAIA Biotechnology
MAIA

33 hedge funds and large institutions have $18.4M invested in MAIA Biotechnology in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more capital invested

Capital invested by funds: $4.09M → $18.4M (+$14.3M)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

27% more funds holding

Funds holding: 26 → 33 (+7)

14.88% more ownership

Funds ownership: 6.8% → 21.68% (+15%)

Holders
33
Holders Change
+7
Holders Change %
+26.92%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
7
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Solas Capital Management
Connecticut
+$7.92M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$4.61M
3
6CM
683 Capital Management
New York
+$1.97M
4
CCC
Cable Car Capital
California
+$1.2M
5
BL
Bleichroeder LP
New York
+$922K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$120K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21.9K
3
SG
StoneX Group
New York
-$15.7K
4
Citigroup
Citigroup
New York
-$3.16K
5
SA
SRH Advisors
Kansas
-$999
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Solas Capital Management
Connecticut
$6.02M +$7.92M +4,297,004 New
Alyeska Investment Group
2
Alyeska Investment Group
Illinois
$3.5M +$4.61M +2,500,000 New
VCM
3
Vanguard Capital Management
Pennsylvania
$2.9M +$3.82M +2,074,045 New
6CM
4
683 Capital Management
New York
$1.49M +$1.97M +1,066,666 New
CWM
5
Centric Wealth Management
Illinois
$1.11M +$388K +210,325 +36%
CCC
6
Cable Car Capital
California
$908K +$1.2M +648,503 New
BL
7
Bleichroeder LP
New York
$700K +$922K +500,000 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$505K +$118K +63,741 +21%
VFT
9
Vanguard Fiduciary Trust
Pennsylvania
$279K +$368K +199,314 New
State Street
10
State Street
Massachusetts
$195K +$117K +63,400 +84%
BlackRock
11
BlackRock
New York
$179K +$38.2K +20,733 +19%
CCM
12
Corsair Capital Management
New York
$140K +$184K +100,000 New
Northern Trust
13
Northern Trust
Illinois
$73.6K +$24.9K +13,507 +35%
UBS Group
14
UBS Group
Switzerland
$72.7K +$91.7K +49,747 +2,292%
BCM
15
Bridgeway Capital Management
Texas
$50.4K – – –
PAM
16
PVG Asset Management
Colorado
$46.4K +$62.9K +34,135 New
Creative Planning
17
Creative Planning
Kansas
$40K -$406 -220 -0.8%
RWM
18
Ritholtz Wealth Management
New York
$32.3K – – –
OSAM
19
O'Shaughnessy Asset Management
Connecticut
$28.1K +$37K +20,071 New
CAG
20
Centerpoint Advisory Group
Kansas
$22K – – –
Wealth Enhancement Advisory Services
21
Wealth Enhancement Advisory Services
Minnesota
$19.7K – – –
Morgan Stanley
22
Morgan Stanley
New York
$19.4K +$23.7K +12,859 +1,286%
VGA
23
Vanguard Global Advisers
Pennsylvania
$16K +$21K +11,401 New
CFM
24
Catalyst Funds Management
Australia
$15.1K +$19.9K +10,800 New
Cambridge Investment Research Advisors
25
Cambridge Investment Research Advisors
Iowa
$15K – – –
1
2

MAIA Hedge Fund Activity: Q1 2026 in Review

33 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q1 2026, worth a combined $18.4M — up 350% from $4.09M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new MAIA positions and 5 closed out — a net gain of 9 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Solas Capital Management, opening a new position worth an estimated $7.92M. The largest seller was Jane Street, exiting entirely with an estimated $120K sold.

  • 33 institutional investors held MAIA Biotechnology (MAIA) as of Q1 2026, up from 26 in Q4 2025.
  • Funds reported $18.4M of MAIA Biotechnology stock for Q1 2026, up 350% quarter-over-quarter.
  • 14 funds opened new MAIA Biotechnology positions in Q1 2026 and 5 closed out, a net change of +9 holders.
  • The largest MAIA Biotechnology buyer in Q1 2026 was Solas Capital Management, an estimated $7.92M added.
  • The largest MAIA Biotechnology seller in Q1 2026 was Jane Street, an estimated $120K sold.

Based on aggregated 13F filings for Q1 2026.